Hostname: page-component-7c8c6479df-5xszh Total loading time: 0 Render date: 2024-03-28T20:38:33.779Z Has data issue: false hasContentIssue false

Economics of treatment of depression

Published online by Cambridge University Press:  02 January 2018

N. Freemantle
Affiliation:
NHS Centre for Reviews and Dissemination, University of York, York Y01 5DD
A. House
Affiliation:
NHS Centre for Reviews and Dissemination, University of York, York Y01 5DD
J. Mason
Affiliation:
NHS Centre for Reviews and Dissemination, University of York, York Y01 5DD
F. Song
Affiliation:
NHS Centre for Reviews and Dissemination, University of York, York Y01 5DD
T. Sheldon
Affiliation:
NHS Centre for Reviews and Dissemination, University of York, York Y01 5DD
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Copyright
Copyright © 1995 The Royal College of Psychiatrists 

References

Dunbar, G. C., Cohn, J. B., Fabre, L. F. et al (1991) A comparison of paroxetine, imipramine and placebo in depressed outpatients. British Journal of Psychiatry, 159, 394398.Google Scholar
Jönsson, B. & Bebbington, P. (1993) Economic studies of the treatment of depressive illness. In Health Economics of Depression, pp 3548. Chichester: John Wiley.Google Scholar
Hillman, A., Eisenberg, J. M., Pauley, M. V., et al (1991) Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine, 324, 13621365.Google Scholar
Song, F., Freemantle, N., Sheldon, T. A., et al (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Medical Journal, 306, 683687.Google Scholar
Stepney, R. (1992) New depression drugs cut costs. MIMS Magazine Weekly, 2 June, 23.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.